Research programme: hepatitis B ribozyme therapy - Viratis
Latest Information Update: 11 May 2010
At a glance
- Originator Viratis
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 13 Aug 2007 Preclinical trials in Hepatitis B in United Kingdom (unspecified route)